Abstract:BACKGROUND:Immunotherapy targeting programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) has been shown to be effective in a variety of malignancies but has poor efficacy in pancreatic ductal adenocarcinoma (PDAC). Studies have shown that PD-L1 expression in tumors is an important indicator of the efficacy of immunotherapy. Tumor cells usually evade chemotherapy and host immune surveillance by epigenetic changes. Protein arginine methylation is a common posttranslational modification. Protein arginine methyltransferase (PRMT) 1 is deregulated in a wide variety of cancer types, whose biological role in tumor immunity is undefined. AIM:To investigate the combined effects and underlying mechanisms of anti-PD-L1 and type I PRMT inhibitor in pancreatic cancer in vivo. METHODS:PT1001B is a novel type I PRMT inhibitor with strong activity and good selectivity. A mouse model of subcutaneous Panc02-derived tumors was used to evaluate drug efficacy, toxic and side effects, and tumor growth in vivo. By flow cytometry, we determined the expression of key immune checkpoint proteins, detected the apoptosis in tumor tissues, and analyzed the immune cells. Immunohistochemistry staining for cellular proliferation-associated nuclear protein Ki67, TUNEL assay, and PRMT1/PD-L1 immunofluorescence were used to elucidate the underlying molecular mechanism of the antitumor effect. RESULTS:Cultured Panc02 cells did not express PD-L1 in vitro, but tumor cells derived from Panc02 transplanted tumors expressed PD-L1. The therapeutic efficacy of anti-PD-L1 mAb was significantly enhanced by the addition of PT1001B as measured by tumor volume (1054.00 ± 61.37 mm3 vs 555.80 ± 74.42 mm3, P < 0.01) and tumor weight (0.83 ± 0.06 g vs 0.38 ± 0.02 g, P < 0.05). PT1001B improved antitumor immunity by inhibiting PD-L1 expression on tumor cells (32.74% ± 5.89% vs 17.95% ± 1.92%, P < 0.05). The combination therapy upregulated tumor-infiltrating CD8+ T lymphocytes (23.75% ± 3.20% vs 73.34% ± 4.35%, P < 0.01) and decreased PD-1+ leukocytes (35.77% ± 3.30% vs 6.48% ± 1.08%, P < 0.001) in tumor tissue compared to the control. In addition, PT1001B amplified the inhibitory effect of anti-PD-L1 on tumor cell proliferation and enhanced the induction of tumor cell apoptosis. PRMT1 downregulation was correlated with PD-L1 downregulation. CONCLUSION:PT1001B enhances antitumor immunity and combining it with anti-PD-L1 checkpoint inhibitors provides a potential strategy to overcome anti-PD-L1 resistance in PDAC.

Inhibition Activity of BF-30 against Murine Pancreatic Carcinoma Cell Panc02 in vitro Abstract

Lysimachia capillipes inhibits proliferation of pancreatic cancer BxPC-3 cells in vitro

Anti-tumor Activity of Emodin on Human Pancreatic Cancer Cell Line BXPC-3 in Vivo

Effect of 5-Lox/cox-2 Common Inhibitor Dhdmbf30 on Pancreatic Cancer Cell Capan2

The Effects of Mirnas-107 on Cell Proliferation, Senescence and Invasion of Pancreatic Cancer PANC-1 Cells

Functional Expression of B7H1 on Pancreatic Carcinoma Panc-1 Cells

Parthenolide Induces Proliferation Inhibition and Apoptosis of Pancreatic Cancer Cells in Vitro

Synthetic small peptides acting on B7H1 enhance apoptosis in pancreatic cancer cells.

The Antibacterial Activity of BF-30 in Vitro and in Infected Burned Rats is Through Interference with Cytoplasmic Membrane Integrity

Inhibition of human pancreatic cancer by β2-adrenergic antagonist via suppression of invasion

Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis

Inhibition of Protein Phosphatase 2A Sensitizes Pancreatic Cancer to Chemotherapy by Increasing Drug Perfusion Via HIF-1α-VEGF Mediated Angiogenesis.

Design and Biological Evaluation of Novel BF-30 Analogs for the Treatment of Malignant Melanoma.

Topically Applicated Curcumin/gelatin-Blended Nanofibrous Mat Inhibits Pancreatic Adenocarcinoma by Increasing ROS Production and Endoplasmic Reticulum Stress Mediated Apoptosis

Inhibition of Sirt1 Combined with Gemcitabine Therapy for Pancreatic Carcinoma

MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by 213 Bi-C595 radioimmunoconjugate

The marine Penicillium sp. GGF16-1-2 metabolite dicitrinone G inhibits pancreatic angiogenesis by regulating the activation of NLRP3 inflammasome

Influence of Stable Inhibition of XIAP and Survivin Expression on Biological Characteristics of Pancreatic Cancer Cells

IL-29 Exhibits Anti-Tumor Effect on Pan-48 Pancreatic Cancer Cells by Up-regulation of P21 and Bax

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.

The Inhibitory Effect of Resveratrol on the Growth of Pancreatic Cancer Cell Line Panc-1 and Its Related Mechanism